Cargando…
A pilot study on the effect of three hydrocortisone dosing regimen on 17 hydroxyprogesterone levels in patients with congenital adrenal hyperplasia
Autores principales: | Salud, Josephine Leiya Marie F, Ramos-Abad, Lorna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850141/ http://dx.doi.org/10.1186/1687-9856-2013-S1-P123 |
Ejemplares similares
-
An integrated PK‐PD model for cortisol and the 17‐hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia
por: Al‐Kofahi, Mahmoud, et al.
Publicado: (2020) -
Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
por: Merke, Deborah P, et al.
Publicado: (2021) -
SUN-037 Discordant Serum 17-hydroxyprogesterone and Androstenedione in the Management of Congenital Adrenal Hyperplasia: Are 11-oxygenated Androgens Useful?
por: Jha, Smita, et al.
Publicado: (2020) -
Diurnal salivary androstenedione and 17‐hydroxyprogesterone levels in healthy volunteers for monitoring treatment efficacy of patients with congenital adrenal hyperplasia
por: Adriaansen, Bas P. H., et al.
Publicado: (2022) -
Hydrocortisone dosing in children with classic congenital adrenal hyperplasia: results of the German/Austrian registry
por: Hoyer-Kuhn, Heike, et al.
Publicado: (2021)